Thank you for your interest in Norditropin® (somatropin) injection 5 mg, 10 mg, 15 mg, and 30 mg pens. We will experience supply shortages of this medication throughout 2023. We apologize for these difficulties and are committed to resolving this issue. Please click here for more details.
Novo Nordisk is committed to helping you support your patients throughout their treatment. NovoCare® offers benefits verification, savings offers, support with prior authorization submission, and more for Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, 15 mg pens, and Norditropin® (somatropin) injection 5 mg, 10 mg, 15 mg, 30 mg pens.
Need assistance now? Call 1‑888‑668‑6444, 8:00 am‑8:00 pm ET, Monday‑Friday.
Novo Nordisk is committed to helping you support your patients throughout their treatment. NovoCare® offers benefits verification, savings offers, support with prior authorization submission, and more for Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, 15 mg pens, and Norditropin® (somatropin) injection 5 mg, 10 mg, 15 mg, 30 mg pens.
Need assistance now? Call 1‑888‑668‑6444, 8:00 am‑8:00 pm ET, Monday‑Friday.
To submit a form online:
Click one of the links below, complete the required fields, and sign electronically.
To submit a form offline:
Click one of the links below, download the form, and fax the form when complete to 1‑888‑508‑8200.
In 4 business hours or less, you can verify your patients’ benefits.a You will receive confirmation of Sogroya® or Norditropin® coverage, or, if no coverage is available, names of alternative therapies may be supplied.
To check the status of a request,
call 1-888-668-6444.
aQuickCheck™ benefits verification can be completed within 4 hours only if all required information has been submitted accurately.
Use these forms to request any of the following for your patient: Starter Kit, JumpStart™, NovoCare® Savings Offer, and Device Training.
Once you have submitted the form, you can expect to be contacted by a NovoCare® Case Manager within 72 hours, Monday‑Friday.b
bInaccurate information in your form could delay patient enrollment.
The Patient Starter Kit contains support materials to help patients initiate therapy.
Provided exclusively through NovoCare® upon request.
Request a starter kit for your patient on the Patient Enrollment form, or call 1‑888‑668‑6444.
We will provide information about payer requirements for the PA process and can help with the submission of supporting documents.
If initial insurance claims are denied, NovoCare® can provide assistance through the appeals process.
Call 1‑888‑668‑6444.
If your patients have commercial insurance, they may be eligible for a lower copay with a savings offer. Here patients can request and print their offer.
Our commitment to affordability
JumpStart™
Patients experiencing a gap or delay in insurance coverage may be eligible for a limited supply of free Sogroya® or Norditropin®.
At this time no dose strengths of Norditropin® will be available via JumpStart™ until product supply is fully restored.
Call 1-888-668-6444 to find out more.
Patient Assistance Program (PAP)
Eligible patients prescribed Sogroya® or Norditropin® who do not have adequate insurance coverage can receive medication free of charge.
We anticipate no new patients will be starting Norditropin® PAP until 2024.
NovoCare® offers a website that breaks down health insurance into easy-to-understand terms. From copays to formularies, the site explains the basics and provides helpful tips and resources.
Refer your patients to GD.HealthInsuranceEd.com
Norditropin® is contraindicated in patients with:
Norditropin® (somatropin) injection is indicated for the treatment of pediatric patients with:
Norditropin® is also indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD)
Norditropin® is contraindicated in patients with:
Please click here for Prescribing Information.
Sogroya® is contraindicated in patients with:
Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg is indicated for the:
Sogroya® is contraindicated in patients with:
Please click here for Sogroya® Prescribing Information.
Norditropin® is contraindicated in patients with:
Norditropin® (somatropin) injection is indicated for the treatment of pediatric patients with:
Norditropin® is also indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD)
Norditropin® is contraindicated in patients with:
Please click here for Prescribing Information.
Sogroya® is contraindicated in patients with:
Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg is indicated for the:
Sogroya® is contraindicated in patients with:
Please click here for Sogroya® Prescribing Information.